X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5758) 5758
Book Review (1475) 1475
Publication (591) 591
Conference Proceeding (27) 27
Book Chapter (18) 18
Magazine Article (5) 5
Book / eBook (1) 1
Data Set (1) 1
Dissertation (1) 1
Government Document (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4974) 4974
index medicus (4939) 4939
cetuximab (4646) 4646
oncology (3353) 3353
female (2196) 2196
male (2062) 2062
chemotherapy (1925) 1925
cancer (1838) 1838
middle aged (1808) 1808
antibodies, monoclonal, humanized (1803) 1803
antineoplastic agents - therapeutic use (1791) 1791
antineoplastic combined chemotherapy protocols - therapeutic use (1672) 1672
aged (1667) 1667
antibodies, monoclonal - therapeutic use (1619) 1619
colorectal neoplasms - drug therapy (1613) 1613
colorectal cancer (1463) 1463
adult (1296) 1296
receptor, epidermal growth factor - antagonists & inhibitors (1196) 1196
treatment outcome (1162) 1162
growth-factor receptor (1129) 1129
colorectal neoplasms - pathology (1027) 1027
care and treatment (942) 942
mutation (932) 932
bevacizumab (910) 910
metastasis (854) 854
egfr (838) 838
colorectal neoplasms - genetics (834) 834
animals (816) 816
antibodies, monoclonal - administration & dosage (788) 788
epidermal growth factor (763) 763
aged, 80 and over (741) 741
1st-line treatment (736) 736
therapy (714) 714
prognosis (671) 671
tumors (671) 671
disease-free survival (669) 669
panitumumab (668) 668
research (659) 659
fluorouracil (634) 634
hematology, oncology and palliative medicine (624) 624
cell line, tumor (607) 607
monoclonal antibodies (605) 605
camptothecin - analogs & derivatives (600) 600
receptor, epidermal growth factor - metabolism (594) 594
carcinoma, squamous cell - drug therapy (592) 592
neoplasm metastasis (591) 591
head and neck neoplasms - drug therapy (580) 580
radiotherapy (579) 579
analysis (577) 577
ras proteins - genetics (577) 577
oxaliplatin (575) 575
metastatic colorectal-cancer (572) 572
survival (566) 566
expression (543) 543
squamous-cell carcinoma (543) 543
antineoplastic agents (533) 533
proto-oncogene proteins p21 (526) 526
pharmacology & pharmacy (524) 524
proto-oncogene proteins - genetics (515) 515
antibodies, monoclonal - adverse effects (510) 510
medicine & public health (500) 500
antimitotic agents (497) 497
drug therapy (497) 497
fluorouracil - administration & dosage (492) 492
squamous cell carcinoma (481) 481
mice (475) 475
antineoplastic agents - pharmacology (471) 471
health aspects (466) 466
antineoplastic agents - adverse effects (457) 457
kras (457) 457
neoplasm staging (456) 456
irinotecan (451) 451
cancer therapies (449) 449
antineoplastic combined chemotherapy protocols - adverse effects (442) 442
retrospective studies (441) 441
trial (438) 438
camptothecin - administration & dosage (429) 429
lung neoplasms - drug therapy (429) 429
epidermal growth factor receptor (424) 424
leucovorin (422) 422
receptor, epidermal growth factor - genetics (419) 419
head and neck cancer (413) 413
phase-iii trial (411) 411
cisplatin (408) 408
antibodies, monoclonal, humanized - therapeutic use (407) 407
cell lung-cancer (407) 407
surgery (398) 398
plus cetuximab (391) 391
carcinoma (382) 382
cetuximab - therapeutic use (373) 373
antibodies, monoclonal - pharmacology (370) 370
colorectal-cancer (369) 369
gefitinib (366) 366
genetic aspects (366) 366
patients (365) 365
clinical trials (364) 364
survival rate (361) 361
colorectal neoplasms - mortality (360) 360
combined modality therapy (359) 359
cetuximab plus irinotecan (358) 358
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5488) 5488
Japanese (92) 92
French (71) 71
German (49) 49
Chinese (24) 24
Spanish (18) 18
Hungarian (13) 13
Czech (6) 6
Italian (5) 5
Korean (5) 5
Dutch (3) 3
Polish (3) 3
Finnish (2) 2
Norwegian (2) 2
Russian (2) 2
Danish (1) 1
Hebrew (1) 1
Persian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1065 - 1075
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2013, Volume 19, Issue 19, pp. 5505 - 5512
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma(1). However, colon... 
PANITUMUMAB | TARGET | CETUXIMAB | MELANOMA | BRAF MUTATIONS | MULTIDISCIPLINARY SCIENCES | PAPILLARY THYROID-CARCINOMA | KRAS | METASTATIC COLORECTAL-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Tumors | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article